Search company, investor...

Pharmasset

pharmasset.com

Founded Year

1998

Stage

Acq - P2P | Acquired

Total Raised

$51.31M

Valuation

$0000 

About Pharmasset

Pharmasset is a clinical-stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections. Pharmasset's primary focus is the development of oral therapeutics for the treatment of hepatitis C virus (HCV) infection. Pharmasset's research and development efforts are focused on nucleoside/tide analogs, a class of compounds which act as alternative substrates for the viral polymerase, thus inhibiting viral replication. In January 2012, Pharmasset was acquired by Gilead Sciences. The valuation of Pharmasset was $11.2 billion.

Headquarters Location

303 College Road E A

Princeton, New Jersey, 08540,

United States

609-613-4100

Missing: Pharmasset's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Pharmasset's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Pharmasset Patents

Pharmasset has filed 8 patents.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

1/4/2008

2/14/2012

Prodrugs, HIV/AIDS, Virology, Antivirals, Animal viral diseases

Grant

Application Date

1/4/2008

Grant Date

2/14/2012

Title

Related Topics

Prodrugs, HIV/AIDS, Virology, Antivirals, Animal viral diseases

Status

Grant

Latest Pharmasset News

Syncona : Resolution Therapeutics Appoints Bill Symonds to its Board of Directors

Jul 20, 2022

07/20/2022 | 04:44am EDT Message : *Required fields 20 July, 2022 - Resolution Therapeutics Limited ("Resolution"), a biopharmaceutical company developing macrophage cell therapies to treat advanced liver disease, today announced the appointment of Dr. Bill Symonds as a Non-Executive Director of the Company. Bill brings experience in drug development and building biotech businesses gained over an accomplished and successful 30-year career in the industry. "It is a huge pleasure to welcome Bill to our Board of Directors. He is an accomplished executive with expertise in bringing transformative therapies to market and building successful development organisations. Having developed and commercialised Solvadi® and Harvoni®, the leading HCV treatments, Bill brings a deep understanding of drug development in advanced liver disease," said Edward Hodgkin, Partner of Syncona Investment Management Limited who serves as Chairman and CEO of Resolution. "I look forward to working with Bill as Resolution grows into an industry-leading company with a pipeline of macrophage cell therapies designed to treat patients with liver cirrhosis." "I'm delighted to be joining Resolution at this important stage in the company's growth," added Bill Symonds. "The Company is the leader in the development of macrophage cell therapy for advanced liver disease, and I look forward to working with the experienced team to bring badly-needed treatments to patients with the potential to avoid the need for liver transplantation." Dr. Symonds currently serves as the Chief Executive Officer of Altavant Sciences and Enzyvant Sciences, both Sumitovant wholly-owned subsidiaries. Previously, Dr. Symonds was a member of the founding management team at Roivant Sciences, Inc., where he served as Chief Development Officer. Earlier in his career, Dr. Symonds held senior positions at a number of pharmaceutical companies, including Pharmasset, Inc. where he led the development of hepatitis C virus infection medicine Solvadi®.Pharmasset was later acquired by Gilead where he continued to serve as VP Liver Disease Therapeutic Area and progressed Solvadi® as well as Harvoni® through to FDA approval. Prior to Pharmasset, Dr. Symonds worked at GSK on numerous medicines for HIV infection. Dr. Symonds received his Doctor of Pharmacy from Campbell University and completed a fellowship in clinical pharmacokinetics at the Clinical Pharmacokinetics Laboratory at Millard Fillmore Hospital in Buffalo, New York. He has authored or co-authored over 35 clinical articles and is named on nine patents related to the composition of matter and methods of use of drugs for hepatitis C infection. - Ends -

Pharmasset Frequently Asked Questions (FAQ)

  • When was Pharmasset founded?

    Pharmasset was founded in 1998.

  • Where is Pharmasset's headquarters?

    Pharmasset's headquarters is located at 303 College Road E, Princeton.

  • What is Pharmasset's latest funding round?

    Pharmasset's latest funding round is Acq - P2P.

  • How much did Pharmasset raise?

    Pharmasset raised a total of $51.31M.

  • Who are the investors of Pharmasset?

    Investors of Pharmasset include Gilead Sciences, MPM Capital, TVM Capital, Burrill & Company, Lumira Ventures and 4 more.

  • Who are Pharmasset's competitors?

    Competitors of Pharmasset include Sierra Oncology, Blue Heron Biotech, GenVec, Cebix, Jennerex Biotherapeutics and 10 more.

Compare Pharmasset to Competitors

E
Epeius Biotechnologies

Scientists at Epeius Biotechnologies have developed a targeted delivery system (TDS) that can transport genes or other therapeutic agents directly to diseased areas in the body. This pathotropic, or disease-seeking, technology has enabled the company to develop Rexin-G, a tumor-targeted, injectable gene delivery system that has demonstrated remarkable safety and single-agent efficacy in clinical trials internationally. Rexin-G is currently in clinical trials for pancreatic cancer in the U.S. ƒƒ‚ƒš‚" where it has achieved FDA orphan drug status ƒƒ‚ƒš‚" and has accelerated approval in the Philippines for the treatment of all solid tumors that are resistant to standard chemotherapy. The company's international clinical outreach with Rexin-G has enabled us to expedite further demonstrations that Rexin-G is highly active in a broad spectrum of chemo-resistant tumor types with efficacy and excellent safety profiles. The company are a biopharmaceutical company focused on expanding the therapeutic utility and commercialization of the company's pathotropic approach to disease treatment through internal development and commercialization of the company's oncology products and cancer vaccines, and through strategic partnerships in additional areas of oncology, immunology, cardiovascular, ocular, and wound healing applications, precision targeted diagnostics, and stem cell technologies.

V
Vector Biolabs

Vector Biolabs is a biotechnology company focused on developing robust gene delivery products, by using its technologies. The company's products are to be used in scientific research, target identification and drug development.

DNAtriX Logo
DNAtriX

DNAtrix is developing modified viruses for the treatment of the most aggressive forms of cancer. Since viruses are already efficient at killing cells, scientists have harnessed this ability by modifying a common cold virus so that it targets and selectively kills cancer cells.

P
ParentPlus

ParentPlus LLC was formed to alleviate male-factor subfertility by bringing biotechnology to millions of subfertile couples for whom intra-uterine insemination (IUI) might be an appropriate therapy. This therapy, with spousal or donor sperm, is underutilized perhaps in part because it frequently is neglected in the popular press. It is the company's belief that sperm from many subfertile men should be the target of a therapy based on modern biotechnology. Successful application of this concept could allow far more subfertile couples, when male-factor subfertility is a problem, to use IUI with spousal sperm to fulfill their dream of a having a baby. Hence, the focus of ParentPlus LLC is on reproductive media to enhance success primarily via IUI, but also enhancing IVF. In due course, demonstrated increased success rate with IUI using ParentPlus products will increase acceptance of IUI as the low cost alternative to highly publicized expensive treatments.

A
Aliva Biopharmaceuticals

Aliva Biopharmaceuticals is a company that received a SBIR Phase I grant for a project entitled: Humanized Mouse Ig system employing BAC. Their research project aims to introduce the entire human immunoglobulin locus into the mouse in order to enable the subsequent production of completely humanized monoclonal antibodies from hybridomas. Monoclonal antibodies against cell surface proteins are currently being used for a variety of clinical indications, including cancer and autoimmunity. Their binding avidity and specificity make them one of the most important modes of therapy for the treatment of a variety of diseases where specific targeting is required. The current technology is based on a system where only 80% of the immunoglobulin locus has been humanized. Replacement of the remaining mouse genes with the human ones will improve the quality and diversity of the antibodies produced and as such, will be an important contribution to this important therapeutic modality.

Dicerna Pharmaceuticals Logo
Dicerna Pharmaceuticals

Dicerna Pharmaceuticals is a pharmaceutical company developing RNA interference (RNAi)-based therapeutics against genetically-defined targets in multiple disease areas, including cancer. Dicerna's therapeutic approach utilizes its Dicer Substrate siRNA (DsiRNA) molecules and EnCore drug delivery technologies to silence previously undruggable disease targets, offering a potential new treatment option for patients. Dicerna delivers its DsiRNA molecules to cancer cells using its EnCore lipid nanoparticle drug delivery technology. EnCore has been specifically engineered to accumulate in tumors and mediate efficient delivery of the DsiRNAs to the RNAi machinery in the cancer cell cytoplasm. Encore particles are well tolerated and manufactured using well-established unit operations to ensure commercial scalability.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.